Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on BIOTIE THERAPIES OYJ. We currently have 3 research reports from 1 professional analysts.
|30Sep16 12:15||GNW||ACORDA GAINS TITLE TO BIOTIE SHARES AND THE SHARES WILL DELIST|
|26Sep16 07:30||GNW||ARBITRAL TRIBUNAL CONFIRMED ACORDA'S REDEMPTION RIGHT REGARDING BIOTIE SHARES AND BIOTIE SHARES TRADING HAS BEEN TERMINATED|
|26Aug16 12:30||GNW||Biotie: BTT1023 receives Orphan Drug Designation in the United States|
|25Aug16 12:15||GNW||THE LISTING COMMITTEE OF NASDAQ HELSINKI HAS RESOLVED TO DELIST THE SHARES OF BIOTIE THERAPIES CORP.|
|18Aug16 07:55||GNW||BIOTIE THERAPIES CORP. APPLIES FOR DELISTING OF ITS SHARES FROM NASDAQ HELSINKI|
|28Jul16 07:00||GNW||Biotie Therapies Corp.'s Interim Report for the reporting period January 1 - June 30, 2016|
|19Jul16 07:01||GNW||ARBITRATORS APPOINTED FOR THE REDEMPTION PROCEEDINGS OF BIOTIE'S MINORITY SHARES|
Frequency of research reports
Research reports on
BIOTIE THERAPIES OYJ
BIOTIE THERAPIES OYJ
Biotie strikes Acord(a) with PD franchise
19 Jan 16
Acorda Therapeutics has made an all-cash offer for Biotie at €0.2946 per share, a 95% premium to the previous close price, valuing the company at €321m (ex. options). Our last published valuation was €0.28/share. The timing of the deal is relevant in the context that the primary Phase III study for tozadenant in Parkinson’s disease (PD) patients is in early stages of recruitment and preliminary data are not expected until end 2017. Biotie’s board has recommended the offer and shareholders representing 59% of the outstanding shares have undertaken to accept Acorda’s proposal.
Pipeline progressing on track
20 Nov 15
Initial recruitment is on track for the Phase III pivotal study (TOZ-PD) of Biotie’s lead product candidate, tozadenant. Tozadenant offers a novel mechanism of action for the treatment of Parkinson’s disease (PD) patients experiencing motor fluctuations on levodopa. Top-line data from the double-blind portion of the trial are expected by end 2017. Meanwhile, two other products, SYN120 (Parkinson’s disease dementia, PDD) and BTT1023 (primary sclerosing cholangitis, PSC), are in Phase II studies; data are expected by end 2016. We value Biotie at €273m, or €0.28/share.
In pivotal territory
01 Sep 15
H115 saw Biotie successfully complete an equity raise through the issue of convertible notes (€33m) and a US IPO (€50m), with net proceeds of €74.3m. The funds raised enabled the start of the pivotal Phase III study, TOZ-PD, for lead product candidate tozadenant in Parkinson’s diseas (PD). Biotie continues to receive a steady stream of royalties from Selincro, a novel treatment concept for alcohol dependence, which is partnered with Lundbeck across Europe. Two other products, SYN120 and BTT1023, are in Phase II trials. We value Biotie at €268m, or €0.27/share.
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
27 Mar 17
Elecosoft* (ELCO): Steadily building profits (CORP) | Bioventix* (BVXP): Interim results lead to upgrades (CORP) | Hurricane Energy (HUR): Halifax discovery (BUY) | KBT Business Technology* (KBT): interims and contract win (CORP) | Independent Oil & Gas* (IOG): Licence updates (CORP)
Interim results lead to upgrades
27 Mar 17
Bioventix reported a strong set of interim results with revenues increasing by 32% (c.12-17% at constant exchange rates (CER)), driven largely by the continued roll-out of its customers’ Vitamin D assay products. This, in turn, led to a 41% increase in pre-tax profits and a 40% increase in adjusted EPS; which is reflective of the operational gearing of the business. We are upgrading our adjusted EPS to 78.7p (+5%) and, consequently, are raising our target price to 1750p. At this price level, the shares would trade on a 22.4x FY 2018 P/E and an EV/EBITDA of 17x. We await confirmation of Siemen’s high sensitivity troponin assay launch, expected in FY 2018.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
Sinclair Pharma - Aesthetically Positioned to Continue Double-Digit Growth
23 Mar 17
With an innovative and differentiated product portfolio of injectable devices addressing the fast-growing aesthetics market, Sinclair is best positioned to continue to achieve double-digit revenue growth in the medium term.
N+1 Singer - Futura Medical - Licensing deal for CSD500 in Portugal
22 Mar 17
The agreement with F Lima further extends the market reach of CSD500, Futura’s erectogenic condom, and brings the total number of distribution partners to eight. The deal is in line with the company’s stated strategy of partnering with leading regional players in the consumer products space. We expect the condom to be launched in Portugal later this year. We retain a positive stance.